Opendata, web and dolomites

oWBI

Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 oWBI project word cloud

Explore the words cloud of the oWBI project. It provides you a very rough idea of what is the project "oWBI" about.

drug    drugs    wearable    bearing    75    9bn    convenient    disposable    doses    flexible    dose    successful    self    administration    market    mechanical    medication    subcutaneous    synthetic    attractive    2025    device    intravenous    body    force    nature    biologically    97m    viscosity    region    customization    trend    depending    grow    components    pharmaceutical    dominated    ed    2020    achievement    company    paired    segment    worn    onto    2015    wbi    seeking    deals    performance    coming    lower    optimal    subcuject    medical    remarkably    bolus    ing    multiple    companies    actively    business    pressure    competitor    wbis    disease    combination    86    licensing    scj    paying    injection    class    profitability    with    commercialize    migrate    accumulated    170    closer    sc    patient    cagr    establishing    eco    significantly    strategy    electronic    prefilled    osmotic    profit    predictable    assist    completion    larger    injectors    moving    formulations    unlike    aps   

Project "oWBI" data sheet

The following table provides information about the project.

Coordinator
SUBCUJECT APS 

Organization address
address: NORDRE STRANDVEJ 119
city: HELLEBAEK
postcode: 3150
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://subcuject.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SUBCUJECT APS DK (HELLEBAEK) coordinator 50˙000.00

Map

 Project objective

With more drugs coming onto the market as combination products, i.e. drug products paired with delivery devices pharmaceutical companies are paying closer attention to integrated delivery systems. Due to: 1) the trend in the change in drug formulations, in order to migrate from intravenous to a more cost-effective and convenient subcutaneous (SC) drug administration; and 2) the trend in moving from synthetic derived drugs to biologically drugs that are more complex and have higher viscosity and therefore require delivery of larger doses; resulted in the need for a new class of injection devices - wearable bolus-injectors (WBIs). WBIs are prefilled, disposable devices that are worn on the body of a patient during the SC self-administration of a large dose of medication. The WBI market is estimated to grow in CAGR of 170% between 2015 – 2020 and achieve €6.9Bn by 2025, and pharmaceutical companies are actively seeking for reliable and cost-effective WBIs, providing optimal injection performance at an attractive unit cost and low cost of customization.

Subcuject ApS (SCJ) is a medical device company set to commercialize a new class of WBIs - Subcuject - that makes use of the simple, predictable and strong force of nature: osmotic pressure. Unlike the current WBIs, Subcuject is fully mechanical, bearing no electronic components, resulting in a more flexible, reliable and eco-friendly device at a remarkably lower cost than competitor’s (75 - 86% cost reduction).

SCJ business strategy is based on establishing multiple licensing deals (depending on the drug type, disease, region) with pharmaceutical companies. The Subcuject device is expected to significantly enhance SCJ’s profitability, with an expected accumulated profit of €97M, 5 years after project completion. Moreover, the successful achievement of the project objectives will assist SCJ to be a leading company in the WBI device segment in a market today dominated by U.S. companies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OWBI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OWBI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

WIMUACT (2017)

TECHNOLOGY FOR THE IMPROVEMENT OF SPORTS PERFORMANCE IN NON-PROFESSIONAL CONTEXTS

Read More  

OE Scan (2018)

A next generation diagnostic device that effectively screens for breast cancer in all tissue types, without the use of ionising radiation

Read More  

DIGISTONE P1 (2014)

Production and Market entry financing of Digital Concrete Screen for Outdoor Digital Signage application

Read More